Print ISSN:-2581-5555

Online ISSN:-2456-9542

CODEN : IIJCDU

Article History

Received : 24-03-2023

Accepted : 30-03-2023



Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 486

PDF Downloaded: 306


A comprehensive review on phytochemistry, nutritional and pharmacological properties of Momordica charantia


Full Text PDF Share on Facebook Share on Twitter


Review Article

Author Details : Pankaj Singh*, Pragati Pandey, Pradeep Kumar Singh, Manikant Tripathi, Rajat Pratap Singh, Shikha Shukla, Neelam Pathak, Ram Lakhan Singh

Volume : 8, Issue : 2, Year : 2023

Article Page : 73-79

https://doi.org/10.18231/j.ijcaap.2023.013



Suggest article by email

Get Permission

Abstract

Momordica charantia is known as the bitter gourd or bitter melon and is a member of the family Cucurbitaceae. It is a medicinal plant and its fruit is consumed as a food also. This plant is grown in tropical as well as subtropical areas around the world, mainly in Asia, India, China, South America and
Brazil. Due to the presence of bioactive compounds like charantin, ?-momorcharin and cucurbitacins, some of which possess potent biological actions, this plant is used in folk medicine all over the world and has many pharmacological activities, like antidiabetic, anticancerous, antimicrobial, antioxidant, antiviral, antimalarial, antihelmintic etc. This plant has been used as traditional medicine in various diseases treatments like syphilis, rheumatism, gout, and illness of the liver and spleen. But mainly M. charantia is famous for its effectiveness in the treatment of diabetes due to the presence of polypeptide-p and is also known as p-insulin due to very similarity in function against diabetes.


Keywords: Antidiabetic, Momordica charantia, Bitter gourd, Antioxidant, Cucurbitacins, Charantin, Polypeptide-p



How to cite : Singh P, Pandey P, Singh P K, Tripathi M, Singh R P, Shukla S, Pathak N, Singh R L, A comprehensive review on phytochemistry, nutritional and pharmacological properties of Momordica charantia. IP Int J Compr Adv Pharmacol 2023;8(2):73-79


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.